Concepts (135)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 22 | 2022 | 3158 | 1.310 |
Why?
|
| Accreditation | 5 | 2019 | 74 | 1.040 |
Why?
|
| Cancer Care Facilities | 4 | 2019 | 36 | 0.950 |
Why?
|
| Quality Assurance, Health Care | 5 | 2014 | 225 | 0.920 |
Why?
|
| Carcinoma, Ductal, Breast | 7 | 2015 | 166 | 0.840 |
Why?
|
| Quality Indicators, Health Care | 4 | 2019 | 154 | 0.750 |
Why?
|
| Carcinoma, Lobular | 5 | 2015 | 84 | 0.690 |
Why?
|
| Mastectomy, Segmental | 3 | 2014 | 108 | 0.640 |
Why?
|
| Registries | 6 | 2015 | 999 | 0.630 |
Why?
|
| Mastectomy | 7 | 2022 | 262 | 0.570 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 3 | 2014 | 122 | 0.480 |
Why?
|
| Data Collection | 4 | 2015 | 370 | 0.480 |
Why?
|
| Rectal Neoplasms | 3 | 2014 | 132 | 0.470 |
Why?
|
| General Surgery | 5 | 2010 | 248 | 0.460 |
Why?
|
| Databases, Factual | 10 | 2018 | 1006 | 0.440 |
Why?
|
| Surgeons | 4 | 2022 | 292 | 0.440 |
Why?
|
| Medical Oncology | 4 | 2010 | 403 | 0.430 |
Why?
|
| Population Surveillance | 3 | 2011 | 214 | 0.420 |
Why?
|
| Patient Care | 2 | 2014 | 97 | 0.400 |
Why?
|
| United States | 20 | 2018 | 7642 | 0.390 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2015 | 1449 | 0.370 |
Why?
|
| Patient Care Team | 1 | 2014 | 298 | 0.350 |
Why?
|
| Neoplasms | 6 | 2014 | 3170 | 0.340 |
Why?
|
| Comprehensive Health Care | 1 | 2011 | 14 | 0.340 |
Why?
|
| Breast Diseases | 1 | 2010 | 99 | 0.310 |
Why?
|
| Hospitals | 3 | 2018 | 330 | 0.300 |
Why?
|
| Neoplasm Staging | 10 | 2018 | 2017 | 0.300 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 446 | 0.240 |
Why?
|
| Global Health | 1 | 2008 | 208 | 0.240 |
Why?
|
| Mammaplasty | 2 | 2022 | 122 | 0.240 |
Why?
|
| Ergonomics | 3 | 2022 | 25 | 0.240 |
Why?
|
| Female | 26 | 2022 | 48781 | 0.230 |
Why?
|
| Humans | 34 | 2022 | 93613 | 0.210 |
Why?
|
| Aged, 80 and over | 13 | 2018 | 7072 | 0.200 |
Why?
|
| Brachytherapy | 2 | 2014 | 126 | 0.190 |
Why?
|
| Mastectomy, Subcutaneous | 1 | 2022 | 8 | 0.180 |
Why?
|
| Quality Control | 4 | 2019 | 123 | 0.180 |
Why?
|
| Mammography | 2 | 2011 | 494 | 0.170 |
Why?
|
| Guideline Adherence | 2 | 2016 | 237 | 0.170 |
Why?
|
| Prognosis | 8 | 2019 | 3915 | 0.160 |
Why?
|
| Quality Improvement | 2 | 2015 | 485 | 0.160 |
Why?
|
| Specialty Boards | 1 | 1999 | 22 | 0.150 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2018 | 86 | 0.150 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 47 | 0.150 |
Why?
|
| Sentinel Lymph Node | 1 | 2018 | 22 | 0.140 |
Why?
|
| Interdisciplinary Communication | 2 | 2010 | 134 | 0.140 |
Why?
|
| Lymph Nodes | 2 | 2015 | 548 | 0.140 |
Why?
|
| Patient Transfer | 1 | 2018 | 108 | 0.130 |
Why?
|
| Aged | 14 | 2018 | 20472 | 0.130 |
Why?
|
| Time-to-Treatment | 1 | 2018 | 140 | 0.130 |
Why?
|
| Biopsy | 2 | 2014 | 1177 | 0.130 |
Why?
|
| Nipples | 3 | 2022 | 37 | 0.130 |
Why?
|
| Follow-Up Studies | 7 | 2019 | 3837 | 0.120 |
Why?
|
| Societies, Medical | 3 | 2014 | 623 | 0.120 |
Why?
|
| Breast | 1 | 1998 | 303 | 0.120 |
Why?
|
| Middle Aged | 14 | 2019 | 27623 | 0.120 |
Why?
|
| Lost to Follow-Up | 1 | 2015 | 15 | 0.110 |
Why?
|
| Clinical Coding | 1 | 2015 | 23 | 0.110 |
Why?
|
| Parathyroid Neoplasms | 1 | 2015 | 60 | 0.110 |
Why?
|
| Personnel, Hospital | 1 | 2015 | 31 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 1055 | 0.110 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 68 | 0.110 |
Why?
|
| Medical Records | 1 | 2015 | 122 | 0.110 |
Why?
|
| Combined Modality Therapy | 3 | 2018 | 1723 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 2 | 2015 | 572 | 0.090 |
Why?
|
| Leadership | 1 | 2014 | 149 | 0.090 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 155 | 0.090 |
Why?
|
| Carcinoma | 1 | 2015 | 439 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 188 | 0.090 |
Why?
|
| Melanoma | 1 | 2016 | 495 | 0.090 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2015 | 315 | 0.080 |
Why?
|
| Workload | 2 | 2022 | 126 | 0.080 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 621 | 0.080 |
Why?
|
| Operating Rooms | 2 | 2022 | 137 | 0.080 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 889 | 0.080 |
Why?
|
| Adult | 10 | 2016 | 27949 | 0.080 |
Why?
|
| Patient Selection | 1 | 2013 | 690 | 0.080 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2009 | 48 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2021 | 4563 | 0.070 |
Why?
|
| History, 20th Century | 1 | 2010 | 314 | 0.070 |
Why?
|
| Total Quality Management | 1 | 2008 | 32 | 0.070 |
Why?
|
| Young Adult | 4 | 2015 | 6937 | 0.070 |
Why?
|
| Program Development | 1 | 2008 | 131 | 0.070 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2007 | 35 | 0.070 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2007 | 71 | 0.060 |
Why?
|
| Drug Utilization | 1 | 2007 | 64 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2008 | 315 | 0.060 |
Why?
|
| Healthcare Disparities | 1 | 2012 | 498 | 0.060 |
Why?
|
| Survival Rate | 3 | 2015 | 1951 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2007 | 152 | 0.060 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 2804 | 0.060 |
Why?
|
| American Cancer Society | 2 | 2004 | 13 | 0.060 |
Why?
|
| Axilla | 2 | 2018 | 109 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2007 | 512 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2014 | 9110 | 0.060 |
Why?
|
| Health Care Surveys | 2 | 2018 | 286 | 0.050 |
Why?
|
| Neoplasm Grading | 2 | 2018 | 402 | 0.050 |
Why?
|
| Disease-Free Survival | 1 | 2007 | 1171 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2016 | 505 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 472 | 0.050 |
Why?
|
| Male | 5 | 2016 | 44582 | 0.050 |
Why?
|
| Health Policy | 1 | 2004 | 207 | 0.040 |
Why?
|
| Age Factors | 3 | 2015 | 1907 | 0.040 |
Why?
|
| Time Factors | 1 | 2010 | 5406 | 0.040 |
Why?
|
| Logistic Models | 2 | 2016 | 1245 | 0.040 |
Why?
|
| Reoperation | 2 | 2014 | 703 | 0.040 |
Why?
|
| SEER Program | 2 | 2000 | 235 | 0.040 |
Why?
|
| Databases as Topic | 1 | 2000 | 96 | 0.040 |
Why?
|
| Adolescent | 3 | 2015 | 9612 | 0.030 |
Why?
|
| Information Systems | 1 | 1997 | 29 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 1998 | 139 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2018 | 237 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 712 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 917 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 359 | 0.030 |
Why?
|
| Sex Factors | 2 | 2015 | 1104 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 1061 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 196 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 321 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2019 | 10185 | 0.020 |
Why?
|
| Colonic Neoplasms | 1 | 1997 | 579 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2013 | 233 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 1702 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 630 | 0.020 |
Why?
|
| Postmenopause | 1 | 2009 | 106 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 1997 | 1775 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2009 | 1525 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1997 | 2368 | 0.010 |
Why?
|
| Information Services | 1 | 2000 | 22 | 0.010 |
Why?
|
| Hospitals, Community | 1 | 2000 | 33 | 0.010 |
Why?
|
| Mastectomy, Radical | 1 | 1997 | 10 | 0.010 |
Why?
|
| Spain | 1 | 1997 | 33 | 0.010 |
Why?
|
| Indians, North American | 1 | 1997 | 48 | 0.010 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1997 | 135 | 0.010 |
Why?
|
| Educational Status | 1 | 1995 | 197 | 0.010 |
Why?
|